Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD1 | P11586 | 3/20 | 0.68 |
| ▸ | DHFR | P00374 | 2/20 | 0.65 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.59 |
| ▸ | FPGS | Q05932 | 2/20 | 0.52 |
| ▸ | MTHFD2 | P13995 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ATIC | P31939 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TYMS | P04818 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomefolic Acid SCHEMBL16466806 | 1.00 | MTHFD1 (0.68) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| Levomefolic Acid SCHEMBL20440869 | 1.00 | MTHFD1 (0.68) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| Levomefolic Acid SCHEMBL79586 | 1.00 | MTHFD1 (0.68) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| Levomefolic Acid SCHEMBL16490221 | 1.00 | MTHFD1 (0.68) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| Levomefolic Acid SCHEMBL3442396 | 0.99 | MTHFD1 (0.67) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| SCHEMBL26045337 | 0.94 | MTHFD1 (0.60) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| SCHEMBL25849429 | 0.94 | MTHFD1 (0.60) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| SCHEMBL17931045 | 0.93 | MTHFD1 (0.59) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| Ketotrexate SCHEMBL1228871 | 0.92 | MTHFD1 (0.80) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| SCHEMBL26045357 | 0.90 | MTHFD1 (0.59) | MTHFD1DHFRSOSTFPGSMTHFD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025017570-A1 | SYNERGISTIC BIOACTIVE COMPOSITION FOR MODULATING CHOLINE DEHYDROGENASE (CHD) ACTIVITY | Celagenex Research (India) Pvt. Ltd. (IN) | 2025-01-23 | — | — | WO | claimed |
| US-5021417-A | Use of a folinic acid substance as a platelet aggregation inhibitor | SPIRAL RECHERCHE ET DEVELOPPEMENT (FR) | 1991-06-04 | — | — | US | claimed |
| WO-2025017570-A1 | SYNERGISTIC BIOACTIVE COMPOSITION FOR MODULATING CHOLINE DEHYDROGENASE (CHD) ACTIVITY | Celagenex Research (India) Pvt. Ltd. (IN) | 2025-01-23 | — | — | WO | disclosed |
| US-20240358740-A1 | FOLIC COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC NEUROPATHIES | CROSS III WILLIAM H (US) | 2024-10-31 | — | — | US | disclosed |
| US-12029750-B2 | Folic compositions and methods for treatment of diabetic neuropathies | CROSS III WILLIAM H (US) | 2024-07-09 | — | — | US | disclosed |
| CN-115611899-B | Preparation method of L-5-methyltetrahydrophthalic acid | 无锡紫杉药业股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-117886819-A | Synthesis method of L-5-methyltetrahydrofolate and calcium salt thereof | 无锡紫杉药业股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117186102-A | Preparation method of N2-methylamino-tetrahydrofolic acid | 无锡紫杉药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-115611899-A | Preparation method of L-5-methyltetrahydropteroic acid | 无锡紫杉药业股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20220305047-A1 | FOLIC COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC NEUROPATHIES | CROSS III WILLIAM H (US) | 2022-09-29 | — | — | US | disclosed |
| CN-114874216-A | Preparation method of L-5-methyltetrahydrofolic acid | 无锡紫杉药业有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-20160271155-A1 | Vitamin Formulations | NESTEC SA (CH) | 2016-09-22 | — | — | US | disclosed |
| EP-2837632-B1 | Derivatives of triazabicyclo[3.2.1]octane useful for the treatment of proliferative diseases | LIANYUNGANG JINKANG HEXIN PHARMACEUTICAL CO LTD (CN) | 2016-05-18 | — | — | EP | disclosed |
| US-9090623-B2 | Compound JK12A and preparation thereof | LIANYUNGANG JINKANG HEXIN PHARMACEUTICAL CO., LTD. (CN) | 2015-07-28 | — | — | US | disclosed |
| WO-2015077509-A1 | VITAMIN FORMULATIONS | NESTEC S.A. (CH) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015077511-A1 | FORMULATION FOR WATER-SOLUBLE VITAMINS TO INCREASE ORAL ABSORPTION AND BIOAVAILABILITY | NESTEC S.A. (CH) | 2015-05-28 | — | — | WO | disclosed |
| US-20150065708-A1 | COMPOUND JK12A AND PREPARATION THEREOF | LIANYUNGANG JINKANG HEXIN PHARMACEUTICAL CO., LTD. (CN) | 2015-03-05 | — | — | US | disclosed |
| EP-2837632-A1 | COMPOUND JK12A AND PREPARATION THEREOF | Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. (CN) | 2015-02-18 | — | — | EP | disclosed |
| WO-2001030352-A1 | HIGH DOSE FOLIC ACID FOR THE TREATMENT OF HYPERHOMOCYSTEINEMIA | CARY PHARMACEUTICALS INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| US-5021417-A | Use of a folinic acid substance as a platelet aggregation inhibitor | SPIRAL RECHERCHE ET DEVELOPPEMENT (FR) | 1991-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029750-B2 | Folic compositions and methods for treatment of diabetic neuropathies | FOLR2, FPGS, DHFR | MTHFD1 5/4885DHFR 3/4885SOST 1212/4885 |
| US-20150065708-A1 | COMPOUND JK12A AND PREPARATION THEREOF | GRIK5, GRIK2, GRIK1 | MTHFD1 1129/4885DHFR 1177/4885SOST 3514/4885 |
| US-20160271155-A1 | Vitamin Formulations | CYP24A1, VDR, CYP2R1 | MTHFD1 683/4885DHFR 381/4885SOST 409/4885 |
| US-20240358740-A1 | FOLIC COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC NEUROPATHIES | FOLR2, FPGS, DHFR | MTHFD1 5/4885DHFR 3/4885SOST 1212/4885 |
| US-20220305047-A1 | FOLIC COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC NEUROPATHIES | FOLR2, FPGS, DHFR | MTHFD1 5/4885DHFR 3/4885SOST 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.